| Line Item | 2025-11-30 | Y/Y |
|---|---|---|
| Revenue | $2.7M | — |
| Cost of Revenue | $2.6M | — |
| Gross Profit | $18K | — |
| R&D Expense | $923K | — |
| SG&A Expense | $1.6M | — |
| Operating Income | -$2.5M | — |
| Pre-tax Income | -$2.3M | — |
| Income Tax | -$105K | — |
| Net Income | -$2.2M | — |
| Line Item | 2025-11-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.3M | +669.0% |
| Accounts Receivable | $73K | +28.5% |
| Current Assets | $12.4M | +3542.7% |
| Total Assets | $13.7M | +648.4% |
| Current Liabilities | $513K | +47.2% |
| Total Liabilities | $513K | +12.7% |
| Stockholders' Equity | $13.2M | +858.7% |
| Line Item | 2025-11-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$2.8M | — |
| Capital Expenditures | $86K | — |
| Investing Cash Flow | -$10.1M | — |
| Financing Cash Flow | $14.0M | — |
| Free Cash Flow | -$2.9M | — |
| EPS (Basic) | -$0.16 | — |
| EPS (Diluted) | -$0.16 | — |